chimeraplast

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Namechimeraplast
Drug Alias Namegene repair technology (Kimeragen)DNA/RNA hybrid (Kimeragen)
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsGenetic Diseases, InbornHemophilia AAnemia, Sickle Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThomas Jefferson University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesValiGen IncThomas Jefferson University
Active IndicationsN/A
Inactive IndicationsGenetic Diseases, InbornHemophilia AAnemia, Sickle Cell +[7] 

Other Information

ATC CodeN/A
Related LinksN/A